Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL - 22/03/24
Abstract |
Diffuse large B-cell lymphoma (DLBCL), a heterogeneous lymphoid malignancy, poses a significant threat to human health. The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a typical cure rate of 50–70%. However, some patients either relapse after complete remission (CR) or exhibit resistance to R-CHOP treatment. Therefore, novel therapeutic approaches are imperative for managing high-risk or refractory DLBCL. Ferroptosis is driven by iron-dependent phospholipid peroxidation, a process that relies on the transition metal iron, reactive oxygen species (ROS), and phospholipids containing polyunsaturated fatty acids-containing phospholipids (PUFA-PLs). Research indicates that ferroptosis is implicated in various carcinogenic and anticancer pathways. Several hematological disorders exhibit heightened sensitivity to cell death induced by ferroptosis. DLBCL cells, in particular, demonstrate an increased demand for iron and an upregulation in the expression of fatty acid synthase. Additionally, there exists a correlation between ferroptosis-associated genes and the prognosis of DLBCL. Therefore, ferroptosis may be a promising novel target for DLBCL therapy. In this review, we elucidate ferroptosis mechanisms, its role in DLBCL, and the potential therapeutic targets in DLBCL. This review offers novel insights into the application of ferroptosis in treatment strategies for DLBCL.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Patients with DLBCL have a risk of relapse or developing resistance to treatment. |
• | DLBCL cells have higher iron demand and increased expression of fatty acid synthase. |
• | Ferroptosis-related genes are linked to DLBCL prognosis. |
• | Ferroptosis may be a promising novel target for treating DLBCL. |
Abbreviations : OH, ABC, ACSL4, AMPK, ART, ATLL, BL, CAC, CAIX, CISD2, CR, CTLs, Dex, DHO, DLBCL, DMF, DMT1, DZNep, EED, EZH2, EZH2i, FAO, FASN, FDA, FTH1, FTL, GCB, GEP, GSH, H3K27, HADHA, HADHB, HFD, ICIs, IKE, IONs, IPI, IRP, IS, ISCs, Len, LIP, LOX, LPCAT3, MS, MUFA-PLs, MZ, NCCD, NCCN-IPI, NCOA4, NFS1, NHL, NOX, OA, PC, PCD, PD-1, PE, PM-DLBCL, POR, PRC2, PUFA-PLs, PUFAs, RCD, R-CHOP, ROS, RTA, SASP, STEAP3, SUZ12, Tf, TfR, TfR-1, TME, UPLC
Keywords : Ferroptosis, diffuse large B-cell lymphoma, iron metabolism, lipid metabolism, therapeutic applications
Plan
Vol 173
Article 116386- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?